Floatz logo

Cerebral Dopamine Neurotrophic Factor

Nervous System Diseases

Herantis Pharma Plc.Phase 1/2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

35 Active assets in the Nervous System Diseases cohort.

Asset / SponsorPhaseRating
Guanfacine
Maimonides Medical Center
Phase 4BB
Ginkgolide
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BB
Guanfacine
Maimonides Medical Center
Phase 4BB
Opc-34712
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3BB
D-thioctic acid
Ain Shams University
Phase 4BB

View all 50 →

Same molecule, other indications

Cerebral Dopamine Neurotrophic Factor is also rated in:

movement disorderDormant
CCC
Indicative ·
55 / 100
View asset →
neurodegenerative diseaseDormant
CCC
Indicative ·
55 / 100
View asset →
brain disorderDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →